2009.9 An experimental vaccine regimen has shown a modest ability to protect people exposed to HIV, the first time an investigational HIV vaccine has been shown to have this effect.
The results from the trial, which involved more than 16,000 adults in Thailand, indicated that the vaccine regimen lowered the rate of contracting HIV by 31% compared with those taking a placebo, according to the U.S. National Institutes of Health, which helped fund the study.
'Additional research is needed to better understand how this vaccine regimen reduced the risk of HIV infection, but certainly this is an encouraging advance for the HIV vaccine field,' said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which is part of the NIH.
It is a rare piece of good news for the field of AIDS vaccine research, which has sponsored more than 100 vaccine trials since 1987 but without any significant success.
The regimen consists of two vaccines. One is a primer dose made by Sanofi Pasteur, the vaccine division of French drug maker Sanofi-Aventis; the other is a booster dose developed by Vaxgen Inc. and now licensed to Global Solutions for Infectious Diseases, in South San Francisco, Calif.
讚助這項研究的美國國立衛生研究院(U.S. National Institutes of Health)的資料顯示，針對泰國逾1.6萬名成人的試驗結果顯示，與服用安慰劑的對照組相比，採用這種免疫疫苗療法的HIV感染率下降了31%。
國 立衛生研究院下屬的國家過敏症與傳染病研究所(National Institute of Allergy and Infectious Diseases)所長法奇(Anthony Fauci)說，還需要進一步研究，以便更好地了解這種免疫法降低HIV感染風險的機制，但這肯定是HIV疫苗領域的一個鼓舞人心的進展。
這 一免疫法由兩種疫苗組成。其一是法國藥品制造商賽諾菲安萬特(Sanofi-Aventis)旗下生產疫苗的子公司Sanofi Pasteur生產的基礎疫苗；另一種是Vaxgen Inc.開發的加強劑，現已授權給位於加州舊金山市的非贏利組織傳染性疾病全球解決方案(Global Solutions for Infectious Diseases)。